NASDAQ$IRON
Disc Medicine Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Disc Medicine reported its second quarter 2025 financial results and provided a business update.
Disc Medicine reported a net loss of $55.2 million for Q2 2025, an increase from $26.4 million in Q2 2024, primarily due to higher operating costs driven by the progression of its clinical pipeline. The company ended the quarter with a strong cash position of $650.0 million, expected to fund operations into 2028.
- Disc Medicine is on track to submit an NDA for bitopertin in erythropoietic protoporphyria (EPP) under the accelerated approval pathway in October 2025.
- The company expects initial data from the Phase 2 study of DISC-0974 in anemia of myelofibrosis (MF) and multiple dose data from the Phase 1b study of DISC-0974 in anemia of non-dialysis-dependent chronic kidney disease (NDD-CKD) in Q4 2025.
- Disc Medicine initiated a Phase 2 study of DISC-3405 in polycythemia vera (PV), with initial data anticipated in 2026.
- The company maintains a strong financial position with $650.0 million in cash, cash equivalents, and marketable securities, providing a cash runway into 2028.
Headline financials
Revenue & EPS history
Disc Medicine · Revenue · Quarterly
$0
Forward guidance
Disc Medicine anticipates significant progress in its clinical pipeline, including regulatory submissions and data readouts, supported by a strong financial position.
Tailwinds
- On track to submit NDA for bitopertin in EPP under accelerated approval pathway in October 2025.
- Expect initial data from Phase 2 study of DISC-0974 in MF anemia in Q4 2025.
- Expect multiple dose data from Phase 1b study of DISC-0974 in NDD-CKD anemia in Q4 2025.
- Initial data from Phase 2 study of DISC-3405 in PV expected in 2026.
- Strong financial position with cash runway into 2028.
Headwinds
- No specific negative forward guidance points were explicitly stated in the report.
- Potential for delays in clinical trials or regulatory approvals.
- Uncertainty of clinical trial outcomes and product commercialization success.
- Competition in the biopharmaceutical market.
- Reliance on key personnel and ability to attract and retain talent.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2025
-0.4%
Avg return
Earnings day
-1.7%
Avg return
5 days after
+3.9%
Avg return
30 days after
56%
10 / 18 earnings
Positive
+14.6%
Q3 2021
Best reaction
-12.4%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +1.3% | -3.8% | -10.2% | |
| Q3 2025 | -1.6% | -2.5% | +5.6% | |
| Q2 2025 | -3.4% | +0.1% | +3.0% | |
| Q1 2025 | +2.3% | +3.8% | +14.1% | |
| Q4 2024 | +0.1% | +1.6% | -3.9% | |
| Q3 2024 | -5.3% | -10.7% | -3.5% | |
| Q1 2024 | +3.5% | +8.5% | +33.3% | |
| Q4 2023 | -8.7% | -9.2% | -56.8% | |
| Q3 2023 | +1.7% | +8.1% | +27.8% | |
| Q2 2023 | +0.3% | +1.9% | -1.2% | |
| Q1 2023 | +0.6% | +1.8% | +47.6% | |
| Q4 2022 | -0.6% | +0.7% | +48.4% | |
| Q3 2022 | -0.6% | -4.7% | -2.4% | |
| Q2 2022 | -12.4% | -10.9% | -31.8% | |
| Q1 2022 | +3.6% | +10.1% | +8.6% | |
| Q4 2021 | -3.2% | -7.7% | -11.0% | |
| Q3 2021 | +14.6% | -5.6% | -12.6% | |
| Q2 2021 | +0.2% | -12.8% | +15.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro